“The present problem has uncovered some structural weaknesses in the EU’s medicines supply chain plus a substantial dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides explained. She advisable that supply chain difficulties be addressed within an EU pharmaceutical techn